Latest Adheris Health (ASX:AHE) News

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.

Adheris Health’s revenue and profit fell sharply in Q4 FY26 due to the previous challenging pharma budget cycle, but the company achieved cashflow break-even and ended the period with $9.5 million in net cash.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Adheris Health has expanded its operating cost reduction program, aiming for more than 30% savings by FY27, while refocusing on high-growth pharmaceutical categories and enhancing its AI-powered patient engagement platform.

Adheris Health reported a sharp decline in Q2 FY26 revenue but is pushing ahead with leadership changes, cost cuts, and a new digital platform to reshape its future.

Adheris Health has received the final $6.1 million holdback payment from its Australian and New Zealand business sale, bringing total proceeds to $33.1 million and setting the stage for future earn-out payments.